RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

• Status: Completed
• Trial end date: 2013-08-01

Summary

The purpose of this study is to test the safety of RAD001 (everolimus) tablets at different dose levels, when added to docetaxel and cisplatin. The investigators want to find out what effects, good and/or bad, that everolimus has when added to docetaxel and cisplatin as treatment for head and neck cancer.

• Phase: Phase 1

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Novartis Pharmaceuticals
• Treatments: Cisplatin; Docetaxel; Everolimus; Sirolimus